AI Engines For more Details: Perplexity Kagi Labs You
Increased Blood Pressure: Methoxamine hydrochloride works by constricting blood vessels, which leads to an increase in blood pressure. This effect is beneficial in treating hypotension and shock, where maintaining adequate blood pressure is crucial for organ perfusion and oxygen delivery.
Treatment of Hypotension: Methoxamine hydrochloride is commonly used in medical settings, such as intensive care units or operating rooms, to raise blood pressure in patients with severe hypotension due to conditions like septic shock, trauma, or anesthesia-induced hypotension.
Side Effects: Like other vasopressors, methoxamine hydrochloride can cause side effects, including hypertension (high blood pressure), reflex bradycardia (slowing of the heart rate), arrhythmias (irregular heartbeats), headache, palpitations, nausea, and vomiting.
Peripheral Vasoconstriction: Methoxamine hydrochloride primarily acts on alpha-1 adrenergic receptors in peripheral blood vessels, leading to vasoconstriction and increased systemic vascular resistance. This effect helps to redistribute blood flow to vital organs during hypotension.
Cardiac Effects: While methoxamine hydrochloride primarily affects peripheral blood vessels, it can also have some direct effects on the heart, including increasing myocardial oxygen demand and potentially worsening ischemia in patients with underlying coronary artery disease.
Contraindications: Methoxamine hydrochloride is contraindicated in patients with hypersensitivity to the drug, pheochromocytoma (a rare adrenal gland tumor), ventricular fibrillation (a life-threatening arrhythmia), and severe peripheral vascular diseases.
Administration and Monitoring: Methoxamine hydrochloride is usually administered intravenously in a controlled medical setting under the supervision of trained healthcare professionals. Close monitoring of blood pressure, heart rate, and other vital signs is essential during its administration to adjust the dosage and prevent adverse effects.
Interactions: Methoxamine hydrochloride may interact with other medications, such as beta-blockers, monoamine oxidase inhibitors (MAOIs), and general anesthetics, potentially leading to additive or antagonistic effects on blood pressure and heart rate.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | -0.3 | |
ADHD | 2.3 | 0.2 | 10.5 |
Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.1 | 5 |
Allergic Rhinitis (Hay Fever) | 0.3 | 1.6 | -4.33 |
Allergies | 3.8 | 1.2 | 2.17 |
Allergy to milk products | 0.3 | 0.4 | -0.33 |
Alopecia (Hair Loss) | 1.1 | 1.1 | |
Alzheimer's disease | 1.7 | 3.5 | -1.06 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.6 | 0.7 | 2.71 |
Ankylosing spondylitis | 1.9 | 0.5 | 2.8 |
Anorexia Nervosa | 0.1 | 1.2 | -11 |
Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
Asthma | 0.8 | 1.3 | -0.63 |
Atherosclerosis | 0.8 | 1.2 | -0.5 |
Atrial fibrillation | 1.6 | 0.5 | 2.2 |
Autism | 4.7 | 5.3 | -0.13 |
Barrett esophagus cancer | 0.3 | 0 | 0 |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 0.2 | 0.9 | -3.5 |
Brain Trauma | 0.8 | 0.5 | 0.6 |
Carcinoma | 2 | 1.7 | 0.18 |
Celiac Disease | 0.8 | 2.7 | -2.38 |
Cerebral Palsy | 0.9 | 0.9 | 0 |
Chronic Fatigue Syndrome | 1.9 | 2.6 | -0.37 |
Chronic Kidney Disease | 1 | 1.2 | -0.2 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.7 | -0.75 |
Chronic Urticaria (Hives) | 0.6 | 0.9 | -0.5 |
Coagulation / Micro clot triggering bacteria | 0.3 | 0.8 | -1.67 |
Colorectal Cancer | 1.8 | 0.8 | 1.25 |
Constipation | 0.5 | 0.8 | -0.6 |
Coronary artery disease | 0.5 | 0.6 | -0.2 |
COVID-19 | 6.5 | 6.2 | 0.05 |
Crohn's Disease | 3.6 | 3.7 | -0.03 |
cystic fibrosis | 0.2 | 0.8 | -3 |
deep vein thrombosis | 0.2 | 0.4 | -1 |
Depression | 5.6 | 4.6 | 0.22 |
Dermatomyositis | 0 | 0.3 | 0 |
Eczema | 0.4 | 0.8 | -1 |
Endometriosis | 1.2 | 0.8 | 0.5 |
Eosinophilic Esophagitis | 0 | 0.3 | 0 |
Epilepsy | 2 | 1.8 | 0.11 |
Fibromyalgia | 1.2 | 0.5 | 1.4 |
Functional constipation / chronic idiopathic constipation | 2.1 | 1.9 | 0.11 |
gallstone disease (gsd) | 1 | 0.7 | 0.43 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.7 | -0.17 |
Generalized anxiety disorder | 0.6 | 1.1 | -0.83 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0 | 0 | |
Graves' disease | 0.9 | 1.4 | -0.56 |
Halitosis | 0.4 | 0 | 0 |
Hashimoto's thyroiditis | 2.2 | 0.4 | 4.5 |
Hidradenitis Suppurativa | 0 | 0.3 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.3 | 0.6 | 2.83 |
hypercholesterolemia (High Cholesterol) | 0.3 | 0.6 | -1 |
hyperglycemia | 0.1 | 1.7 | -16 |
Hyperlipidemia (High Blood Fats) | 1.1 | 0.5 | 1.2 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1.3 | 3.8 | -1.92 |
Hypothyroidism | 0.9 | -0.9 | |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 1.2 | -1.2 | |
Inflammatory Bowel Disease | 1.9 | 4.4 | -1.32 |
Insomnia | 0.5 | 0.8 | -0.6 |
Intelligence | 0.1 | 0.1 | |
Intracranial aneurysms | 0.5 | 0.5 | 0 |
Irritable Bowel Syndrome | 2.2 | 2.1 | 0.05 |
Liver Cirrhosis | 2.3 | 1.6 | 0.44 |
Long COVID | 3.4 | 6.1 | -0.79 |
Low bone mineral density | 0.7 | -0.7 | |
Lung Cancer | 0.3 | 1.1 | -2.67 |
ME/CFS with IBS | 0.3 | 1.5 | -4 |
ME/CFS without IBS | 0.9 | 1 | -0.11 |
Menopause | 1.3 | 1.3 | |
Metabolic Syndrome | 4.3 | 5.2 | -0.21 |
Mood Disorders | 7.2 | 4.8 | 0.5 |
multiple chemical sensitivity [MCS] | 0.6 | 0.4 | 0.5 |
Multiple Sclerosis | 3.1 | 1.8 | 0.72 |
Multiple system atrophy (MSA) | 1.7 | 0.7 | 1.43 |
Neuropathy (all types) | 0.7 | 0.1 | 6 |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 3.9 | -2.55 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 5.5 | 2.6 | 1.12 |
obsessive-compulsive disorder | 2.6 | 2.3 | 0.13 |
Osteoarthritis | 0.4 | 0.4 | |
Osteoporosis | 0.7 | 1 | -0.43 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 2.1 | 1.9 | 0.11 |
Polycystic ovary syndrome | 0.6 | 1.3 | -1.17 |
Postural orthostatic tachycardia syndrome | 0 | 0.3 | 0 |
Premenstrual dysphoric disorder | 1.1 | 0.1 | 10 |
primary biliary cholangitis | 0.2 | 0.5 | -1.5 |
Psoriasis | 3 | 1.2 | 1.5 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.7 | 2.3 | 0.61 |
Rosacea | 0.9 | 0.4 | 1.25 |
Schizophrenia | 4.2 | 1.1 | 2.82 |
scoliosis | 0.7 | -0.7 | |
Sjögren syndrome | 1.6 | 1.7 | -0.06 |
Sleep Apnea | 0.7 | 1.1 | -0.57 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.6 | -2 |
Stress / posttraumatic stress disorder | 1.5 | 2.3 | -0.53 |
Systemic Lupus Erythematosus | 1.7 | 1.6 | 0.06 |
Tic Disorder | 0.2 | 0.9 | -3.5 |
Tourette syndrome | 0.3 | 0.1 | 2 |
Type 1 Diabetes | 1.2 | 1.5 | -0.25 |
Type 2 Diabetes | 4.3 | 3.1 | 0.39 |
Ulcerative colitis | 1.3 | 2 | -0.54 |
Unhealthy Ageing | 2.3 | 1.2 | 0.92 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.